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Background: The α-isoform of the Type 1A Phosphoinositide 3-kinases (PI3Kα) has protein kinase activity as well as
phosphoinositide lipid kinase activity. The best described substrate for its protein kinase activity is its regulatory
subunit, p85α, which becomes phosphorylated on Serine 608. Phosphorylation of Serine 608 has been reported to
down-regulate its lipid kinase activity.
Results: We have assessed whether oncogenic mutants of PI3Kα, which have up-regulated lipid kinase activity,
have altered levels of Serine 608 phosphorylation compared to wild type PI3Kα, and whether differential
phosphorylation of Serine 608 contributes to increased activity of oncogenic forms of PI3Kα with point mutations in
the helical or the kinase domains. Despite markedly increased lipid kinase activity, protein kinase activity was not
altered in oncogenic compared to wild type forms of PI3Kα. By manipulating levels of phosphorylation of Serine
608 in vitro, we found no evidence that the protein kinase activity of PI3Kα affects its phosphoinositide lipid kinase
activity in either wild-type or oncogenic mutants of PI3Kα.
Conclusions: Phosphorylation of p85α S608 is not a significant regulator of wild-type or oncogenic PI3Kα lipid
kinase activity.
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Phosphoinositide 3-kinases (PI3Ks) are a ubiquitous family
of lipid kinases that catalyse the phosphorylation of phos-
phoinositide lipids at the 3’ position on the inositide ring
[1]. The Class 1A sub-group exists as heterodimers of a
p110 catalytic subunit and a p85 regulatory subunit that
can phosphorylate three phosphoinositides (PI, PI-(4)-P
and PI-(4,5)-P2) in vitro, but are thought to primarily
phosphorylate PI-(4,5)-P2 in vivo to form PI-(3,4,5)-P3
(PIP3) [1]. PIP3 resides almost exclusively in the plasma
membrane and propagates signals by recruiting and* Correspondence: wayne.phillips@petermac.org
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reproduction in any medium, provided the oractivating a variety of downstream proteins that contain
PIP3 binding domains (primarily Pleckstrin Homology
(PH) domains) [2]. PI3K/PIP3 signalling regulates a wide
range of cellular processes including cell growth, survival,
glucose metabolism and migration [1,3].
The prototypic Class 1A PI3K is a heterodimer of the
α isoforms of p110 and p85 (p110α/p85α or PI3Kα).
Mutations in PIK3CA, the gene encoding p110α, are
oncogenic [4-7] and are frequently reported in breast
and colon cancers, where they are found in around 25%
of human tumours [8-11]. Tumour-associated PIK3CA
mutations are all somatic, mono-allelic single base
changes that result in single amino acid substitutions.
The majority (>80%) of mutations cluster in exon 9
(which codes for the helical domain) or exon 20 (which
codes for the kinase domain), most commonly E542KLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Cancer-associated, mutated forms of PI3Kα are associated
with increased phosphoinositide kinase activity [4-6,13],
leading to up-regulation of downstream signalling events
such as phosphorylation of Akt and S6 [5,14].
Class 1A PI3Ks also have protein kinase activity. The
p110α catalytic subunit can phosphorylate its regulatory
subunit, p85α, at Serine 608 (S608). Phosphorylation of
this site has been reported to result in feed-back inhi-
bition by down-modulating the lipid kinase activity of
p110α [15-17], however the role of phosphorylation of
S608 in signalling by endogenous PI3Kα and the struc-
tural mechanism of down-modulation of lipid kinase
activity by S608 phosphorylation are not well described.
We have assessed the possibility that the increased lipid
kinase activities of oncogenic mutants of PI3Kα could be
partly due to alterations in the phosphorylation of S608.
Rather than make point mutations in S608, which can
potentially subtly alter the structure and thus the activity
of p110α/p85α heterodimers, we have manipulated the
levels of phosphorylation of S608 of highly-purified,
recombinant p110α/p85α in vitro and tested the effect
on lipid kinase activity. Neither complete dephosphory-
lation nor a high percentage occupancy of S608 by a
phosphate group significantly altered the lipid kinase ac-
tivity of wild-type PI3Kα. The levels and kinetics of S608
phosphorylation in two oncogenic mutants, E545K and
H1047R, were not significantly different to that of wild-
type p110α/p85α and the lipid kinase activities of mutant
PI3Kα were similarly unaffected by phosphorylation of
S608. This suggests that phosphorylation of S608 is not a
significant regulator of PI3Kα lipid kinase activity.Figure 1 Characterisation of purified, recombinant PI3Ks. A. SDS-PAGE
(Fermentas, Lane 1), 0.5 μg purified p110αEEWT/p85α (lane 2), 0.5 μg purifie
(lane4). B. Purified, recombinant PI3Ks were assayed for lipid kinase activity
Reactions were stopped after 20 minutes using 1 M HCl. The amount of 32
displayed as mean ± SEM, n = 4.Results
Expression, purification and characterisation of
recombinant wild-type and mutant PI3Kα
The same strategy that was used to express and purify
active, recombinant bovine p110α/p85α [18] was used to
generate human, C-terminally EE-tagged, full length,
wild-type p110α/p85α in Sf9 insect cells using the
Bac-N-Blue baculovirus system. When Sf9 cells were co-
infected with baculoviruses encoding both subunits, p85
was expressed at higher levels than p110αEE, therefore
to obtain purified p110αEE/p85α, affinity chromatog-
raphy using an antibody directed against the epitope tag
(EE mAb) was used to capture the enzyme complex but
not excess p85α. Competitive elution with an EE-tag
peptide (EYMPME), followed by anion exchange chro-
matography were performed as described [18]. PI3K
purified in this way comprises a homogeneous 1:1 com-
plex of the p110α and p85α subunits as assessed by both
SDS-PAGE (Figure 1A) and analytical size exclusion
chromatography [18]. Recombinant p110αEE/p85α was
estimated to be > 95% pure based on densitometry of the
relative levels of all Coomassie blue-stained bands in
each lane and no peptides other than those derived from
p110αEE or p85α were detected by LC-MS/MS of tryptic
digests of the purified recombinant complex. We have
also expressed and purified to homogeneity EE-tagged
complexes of p85α with p110α containing two of the
most common cancer-associated mutations from two
different regions of p110α (E545K in exon 9 and
H1047R in exon 20) (Figure 1A).
Oncogenic mutants of PI3Kα have been reported to
have higher lipid kinase activity than wild-type [4-6,13].and Coomassie Blue staining of molecular weight standards
d p110αEEE545K/p85α (lane 3) and 0.5 μg purified p110αEEH1047R/p85α
with increasing concentrations of ATP using PI-(4,5)-P2 as a substrate.
P-PI-(3,4,5)-P3 generated was quantified using a phosphorimager and
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p110αEEE545K/p85α and p110αEEH1047R/p85α complexes
have higher lipid kinase activities than p110αEEWT/
p85α. The H1047R mutant had higher activity than the
E545K mutant (Figure 1B). Kinetic parameters were
derived for recombinant wild type and mutant p110αEE/
p85α complexes by varying the concentration of ATP
and measuring initial reaction rates (Table 1), and
showed that, when PI was used as the substrate, the Km
for H1047R and E545K were similar to wild type. When
PI-(4,5)-P2 was used as a substrate, the Km for H1047R
was decreased approximately 2-fold compared to wild
type, but that for E545K was not significantly different.
Both mutants showed a significant 3 to 4-fold increase
in Vmax when either PI or PI-(4,5)-P2 was used as a sub-
strate, with the Vmax for H1047R being significantly
higher than that for E545K (Table 1). The kinetic charac-
teristics of purified, recombinant, EE-tagged forms of
wild-type and mutant PI3Kα are therefore essentially the
same as those previously reported for purified, recom-
binant His-tagged forms of PI3Kα [15,19] and endogen-
ous wild-type and mutant PI3K [4,5].
Effect of dephosphorylation of p85α S608 on PI3Kα lipid
kinase activity
S608 in the p85 subunit is a substrate for the protein
kinase activity of PI3Kα [17, 20]. Phosphorylation of
S608 by p110 is reported to down-regulate PI3Kα lipid
kinase activity [17,20]. This raises the possibility that
higher lipid kinase activities of oncogenic mutants of
PI3Kα could be partly due to alterations in the levels of
phosphorylation of S608.
To better compare lipid kinase activities of wild-type
and mutant PI3Kα that were phosphorylated or unpho-
sphorylated at S608, we opted to manipulate phosphor-
ylation levels of recombinant p110αEE/p85α complexes
in vitro rather than to make point mutations in S608.
To perform lipid kinase assays with dephosphorylated
PI3Kα, it was necessary to find a phosphatase that
dephosphorylated p85α but not inositol lipids. WeTable 1 Kinetic analysis of in vitro lipid kinase activity of
p110αEEWT/p85α, p110αEEE545K/p85α and p110αEEH1047R/
p85α
Wild type E545K H1047R
PI kinase activitya Vmax
b 35 ± 13c 118 ± 12 150 ± 13
Km (μM) 23 ± 3 22 ± 6 14 ± 7
PI-(4,5)-P2 kinase activity Vmax 35 ± 8 117 ± 13 146 ± 15
Km (μM) 22 ± 5 19 ± 6 9 ± 3
aPI or PI-(4,5)-P2 were used as substrates to generate PI-3-P or PI-(3,4,5)-P3.
bMichaelis-Menten kinetic parameters (substrate affinity (Km) and maximum
reaction velocity (Vmax)) for the production of PI-3-P or PI-(3,4,5)-P3 were
calculated from assays in which the concentration of ATP was varied.
cKm and Vmax are shown as mean ± SEM, n = 4.compared three different protein phosphatases (Figure 2A).
We have previously used Antarctic Phosphatase to depho-
sphorylate affinity-precipitated proteins for characterisation
on 2D gels [21], however Antarctic Phosphatase was in-
active at temperatures >4°C that are required for significant
lipid and protein kinase activity of PI3Kα, and so had no
effect on levels of phosphorylation of p85α or PI at room
temperature (Figure 2A). Alkaline phosphatase is a broad
spectrum phosphatase that was able to dephosphorylate
both S608 and PI-3-P. In contrast, recombinant λ phos-
phatase dephosphorylated S608 but not PI-3-P (Figure 2A).
λ phosphatase was therefore added to PI kinase assays to
continually remove phosphate groups from S608 and allow
comparison of the lipid kinase activity of phosphorylated
and dephosphorylated PI3Kα.
As expected, inclusion of λ phosphatase in kinase assays
resulted in no significant incorporation of 32P-labelled
phosphate groups into p85α, demonstrating that levels of
p85α phosphorylation were low in the presence of λ phos-
phatase (Figure 2B, upper panel). Dephosphorylated
p110αEEWT/p85α did not have a significantly different
PI kinase activity to p110αEEWT/p85α that became phos-
phorylated on p85α over the course of the assay
(Figure 2B, lower panel). Similarly, the E545K and
H1047R mutants did not have significantly different PI
kinase activities when p85α was either dephosphorylated
or phosphorylated, although the PI kinase activities of
p110αEEE545K/p85α and p110αEEH1047R/p85α were higher
than that of p110αEEWT/p85α as expected (Figure 2B,
lower panel). Interestingly, as observed previously [15], the
protein kinase activities of p110αEEE545K/p85α and
p110αEEH1047R/p85α were not significantly different to
that of p110αEEWT/p85α (Figure 2B, upper panel).
It is possible that the stoichiometry of phosphorylation
of S608 remains low after the 40 minute kinase reaction
used, and thus lipid kinase activities of dephosphorylated
and only partially phosphorylated p110αEE/p85α were
compared in Figure 2B. We therefore performed a time-
course to determine whether a difference in activity of
phosphorylated and dephosphorylated p110αEE/p85α
became apparent with increasing levels of phosphoryl-
ation of p85α. Levels of phosphorylation of S608 became
saturated after approximately 30 minutes (Figure 2C,
upper panel). In some assays, the level of phosphoryl-
ation of the E545K mutant was apparently higher than
wild-type PI3Kα or the H1047R mutant, although this
was an inconsistent observation and was not signifi-
cantly different in most assays. When λ phosphatase was
added, lack of incorporation of 32P into p85α demon-
strated that λ phosphatase continued to dephosphorylate
S608 throughout the assay. (Figure 2C, lower panel,
closed symbols). Despite apparently saturating phos-
phorylation of S608 between 40 and 120 minutes, the
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Figure 2 Dephosphorylation of p85α S608 does not alter PI kinase activity. A. Dephosphorylation of PI3Kα using different protein
phosphatases. Purified, recombinant p110αEEWT/p85α (200 ng) was assayed for protein (upper panel) or PI (lower panel) kinase activity in the
presence of no phosphatase (control), 2 U Antarctic Phosphatase, 10 U Calf Intestinal Alkaline Phosphatase or 40 U Lambda (λ) Protein
Phosphatase. Reactions were stopped after 30 minutes using 1 M HCl. B. Lipid kinase activity of dephosphorylated wild-type and mutant PI3Kα.
200 ng purified, recombinant p110αEEWT/p85α, p110αEEE545K/p85α or p110αEEH1047R/p85α was assayed for protein kinase activity (upper panel)
or lipid kinase activity using PI as a substrate (lower panel) in the presence or absence of 40 U λ Protein Phosphatase. Reactions were stopped
after 40 minutes using 1 M HCl. C. Time courses of phosphorylation of p85α S608 and PI in the presence or absence of a protein phosphatase.
200 ng purified, recombinant p110αEEWT/p85α (circles), p110αEEE545K/p85α (triangles) or p110αEEH1047R/p85α (squares) was assayed for protein
kinase activity (upper panel) or lipid kinase activity using PI as a substrate (lower panel) in the presence (closed symbols) or absence
(open symbols) of 20 U λ Protein Phosphatase. Reactions were stopped after the indicated times using 1 M HCl.
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PI3Kα did not increase over time (Figure 2C, lower
panel), suggesting that phosphorylation of S608 does not
regulate the PI kinase activity in either wild-type or mu-
tant PI3Kα.
Effect of phosphorylation of p85α S608 on PI3Kα lipid
kinase activity
To ensure that the apparent lack of difference in PI kin-
ase activity of phosphorylated and dephosphorylated
PI3Kα was not due to a low stoichiometry of phosphor-
ylation, even when levels were apparently saturated, we
allowed the phosphorylation reaction to proceed for
16–24 hours using unlabelled ATP or no ATP for the
mock phosphorylation reaction. Phosphorylated and
mock-phosphorylated PI3Kα were buffer exchanged to
remove excess cold ATP, then the extent of phosphoryl-
ation of S608 was measured using MALDI-MS of tryptic
digests of wild-type and mutant PI3Kα. Overlapping
tryptic peptides containing S608 were observed at m/z
3483.4 and m/z 3611.5 in mock or unphosphorylated
PI3Kα (Figure 3A, lower spectrum in each panel). Phos-
phorylation of PI3Kα led to the appearance of peptidesat m/z 3563.5 and m/z 3691.6 (Figure 3A, upper
spectrum in each panel), which are 80 mass units greater
than the masses of the peptides containing non-
phosphorylated S608 and suggest that these peptides
incorporated one phosphate group per peptide. There
was no evidence for phosphorylation of peptides other
than those containing S608. To estimate the extent of
phosphorylation of S608, we normalised the spectra to
the height of a peptide at m/z 3426.6 that is not altered
when PI3Kα is phosphorylated, and compared the
heights of the peaks of non-phosphorylated S608-con-
taining peptides. Phosphorylation of p110αEEWT/p85α
led to almost complete disappearance of the peaks at
m/z 3483.4 and m/z 3611.5 corresponding to non-
phosphorylated S608, suggesting that at least 90% of
p110αEEWT/p85α was phosphorylated on S608 (Figure 3A,
upper spectrum of panel 1). In support of this, the amount
of 32P incorporated into p85α in a subsequent protein
kinase time-course assay was negligible, suggesting
that nearly all S608 residues were already occupied by
an unlabelled phosphate group (Figure 3B, upper
panel). The extent of phosphorylation of p85α S608 in
p110αEEE545K/p85α and p110αEEH1047R/p85α was less
Figure 3 Phosphorylation of p85α S608 does not alter PI kinase activity. 25 μg purified, recombinant p110αEEWT/p85α, p110αEEE545K/p85α
or p110αEEH1047R/p85α was incubated with (phosphorylated) or without (mock) 1 mM ATP for 16 hr. Excess ATP was removed by buffer
exchange into TBS containing 10 mM 2-mercaptoethanol then phosphorylated or mock phosphorylated PI3Kα was concentrated to
approximately 0.5 mg/ml. A. MALDI-MS spectrum from m/z 3400–3750 of a Fe3+ IMAC-enriched tryptic digest from phosphorylated (upper
spectrum) or mock phosphorylated (lower spectrum) p110αEEWT/p85α, p110αEEE545K/p85α and p110αEEH1047R/p85α. The intensity scale for these
spectra were normalised to the peak at m/z 3424.5, which corresponds to a peptide encompassing residues 35–66 from p85α
(35GSLVALGFSDGQEAKPEEIGWLNGYNETTGER66) that is not phosphorylated by the protein kinase activity of p110αEE/p85α. Serine 608 from p85α
was observed within 2 overlapping peptides of m/z 3483.4 corresponding to residues 594–622 from p85α
(594LNEWLGNENTEDQYSLVEDDEDLPHHDEK662) and m/z 3611.5 corresponding to residues 593–622 from p85α
(593KLNEWLGNENTEDQYSLVEDDEDLPHHDEK662). Incubation with ATP resulted in the appearance of peptides of masses m/z 3563.5 and m/z
3691.6 which are 80 mass units (the mass of a phosphoryl- group) greater than m/z 3483.4 and m/z 3611.5. B. 250 ng of phosphorylated
(closed symbols) or mock phosphorylated (open symbols) p110αEEWT/p85α (circles), p110αEEE545K/p85α (triangles) or p110αEEH1047R/p85α
(squares) were assayed for PI (lower panel) or protein (upper panel) kinase activities as described above.
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the peaks at m/z 3483.4 and m/z 3611.5 were less
decreased by phosphorylation compared to the height of
the same peaks in mock-phosphorylated p110αEEE545K/
p85α and p110αEEH1047R/p85α (Figure 3A, panels 2 & 3),
suggesting that a small proportion of mutant PI3Kα
remained unphosphorylated after 16 hours. In agreement,low levels of 32P were incorporated into p85α in subse-
quent protein kinase time-course assays (Figure 3B, upper
panel), suggesting that a small proportion of S608 in the
E545K and H1047R mutants was not occupied by an un-
labelled phosphate group. Nevertheless, the majority of
p110αEEE545K/p85α and p110αEEH1047R/p85α was phos-
phorylated on S608 under these conditions.
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phosphorylated wild-type PI3Kα were not significantly
different over a 2 hour time-course. Similarly, the PI kin-
ase activities of phosphorylated and mock-phosphorylated
E545K and H1047R PI3Kα were not significantly different,
although the activities of H1047R, and to a lesser extent
E545K, were higher than that of wild-type PI3Kα. Nearly
stoichiometric phosphorylation of S608 therefore did not
affect the PI kinase activity of wild-type or mutant PI3Kα,
further suggesting that phosphorylation of S608 does not
regulate PI kinase activity.
Discussion
As reported previously for bovine PI3Kα [18], we have
successfully expressed and purified recombinant com-
plexes of full-length human p110α and p85α, the proto-
typic form of Class 1A PI3K using the strategy of
selecting for the of p110αEE/p85α complex by placing a
6 amino acid epitope tag at the C-terminus of the
p110α, the subunit with limiting expression levels. The
addition of C-terminal EE tag to p110α did not appear
to affect PI3Kα, as recombinant p110αEE/p85α had high
stability and the expected activity and substrate specifi-
city. High purity recombinant PI3Kα allowed us to
assess the relative phosphoinositide lipid and protein
kinase activities of wild-type and two common, tumour-
associated mutants of PI3Kα.
Purified, recombinant oncogenic mutant forms of
PI3Kα had higher lipid kinase activities compared to
wild-type PI3Kα (Figure 1B) as expected [4-6,13]. The
ATP Km was not significantly different between wild-
type and mutant forms of PI3Kα (Table 1) as previously
reported [19]. However, there was a significant difference
in ATP Vmax when either PI or PI-(4,5)-P2 was used as a
substrate, in agreement with a previous study [15]. This
suggests that mutant forms of PI3Kα phosphorylate and
turn over inositol lipids more rapidly, rather than having
inherent higher substrate affinities, thus generating
increased levels of PIP3 and potentially partially explain-
ing increased downstream signalling when the PI3K
pathway is activated.
PI3Kα also has protein kinase activity and has been
reported to phosphorylate a number of protein sub-
strates [22,23] as well as its own p85α regulatory subunit
on S608 [16,17,20]. The role of S608 phosphorylation in
the regulation of PI3Kα lipid kinase activity remains
controversial. Despite previous reports that phosphoryl-
ation of S608 down-regulates the lipid kinase activity of
the p110α catalytic subunit, we did not find any evidence
to support this by in vitro manipulation of the levels of
phosphorylation of S608 of purified, recombinant
p110αEE/p85α using either a protein phosphatase or sat-
urating pre-phosphorylation. The reason for this dis-
crepancy is not clear. In two studies, semi-purifiedrecombinant PI3Kα was used to show phosphorylation
of S608 reduces the lipid kinase activity of p110α
[17,20]. Semi-purified PI3Kα can be unstable, thus it is
possible that the apparent decrease in the lipid kinase
activity of semi-purified PI3Kα over time was due to
p110α degradation rather than S608 phosphorylation. A
number of other studies have not observed a decrease in
lipid kinase activity of recombinant, purified or immuno-
precipitated PI3Kα in time-course assays [24-27].
The time-course of PIP3 formation by endogenous
PI3K in cells shows an initial increase, followed by a de-
crease in PIP3 levels [28,29], but this is largely due to the
action of inositol 3- and 5-phosphatases that directly
dephosphorylate PIP3 to form PI-(4,5)-P2 or PI-(3.4)-P2
respectively [30,31]. The phosphorylation of S608 in cells
increases upon stimulation with insulin or PDGF [16],
which mirrors activation of the lipid kinase activity of
PI3Kα, thus it is not clear whether phosphorylation of
S608 down-regulates endogenous PI3Kα activity. Muta-
tion of S608 to a non-phosphorylatable residue has been
shown to decrease lipid kinase activity rather than increase
it, as would be expected if mutation to alanine prevented
phospho-S608-induced down regulation of PI kinase activ-
ity [16], suggesting that mutation of this residue, which
resides in the interSH2 domain of p85α, affects PI3Kα
lipid kinase activity by altering the structure of PI3Kα ra-
ther than by affecting the phosphorylation status.
Phosphorylation of S608 has also been reported to lead
to dissociation of the p85α and p110α subunits [16].
Free p110α has higher activity than p110α in complex
with p85α but is very unstable and is quickly degraded
[32], thus it is possible that the decrease in lipid kinase
activity when p85α S608 is phosphorylated could be
explained by dissociation of p110α and p85α and rapid
degradation of free p110α. However, our highly purified
recombinant forms of PI3Kα, when phosphorylated to
saturation on p85α S608, showed no evidence of sub-
unit dissociation by size-exclusion chromatography and
no evidence of p110α degradation by SDS-PAGE (data
not shown). The lack of observed dissociation, degrad-
ation or decrease in lipid kinase activity concomitant with
increasing p85α S608 phosphorylation in our highly puri-
fied, recombinant PI3Kα suggests that previous reports of
S608 phosphorylation resulting in down-regulation of lipid
kinase activity were due to the use semi-purified recom-
binant PI3Kα which is non-specifically degraded over
time.
A number of mechanisms that regulate PI3Kα enzym-
atic activity have been described, but no single event has
been demonstrated to result in full activation of this
enzyme. It is likely that full activation of PI3Kα is a
multi-step process. Within the p110α/p85α complex,
p110α is both inhibited and structurally stabilised by
tight binding to the p85α subunit [32]. Activation of the
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the inhibition of the p110α kinase activity that is due to
inter-subunit interactions of p110α with the N-terminal
SH2 and inter-SH2 domains of p85α [33]. One mechan-
ism of activation of PI3Kα is binding to specific
phosphotyrosine-containing motifs (pYXXM) present in
receptor tyrosine kinases (RTKs) and cytoplasmic signal-
ling proteins, such as IRS-1, to the p85α N- and C-
terminal SH2 domains [34-36], which disrupts the
inhibitory contact between the p85α N-terminal SH2
and the p110α catalytic domain [37,38]. The E545K mu-
tation is thought to increase activity by disrupting the
p85α N-terminal SH2/p110α interface, similar to binding
of RTKs [37,38]. Binding of a range of other intracellular
proteins, such as activated Ras, SH3 domain-containing
proteins and small GTPases, have also been reported to
activate PI3Kα [39-41] but it is not clear whether bind-
ing of these ligands directly activates enzyme activity or
whether binding results in activation by translocating
PI3Kα to the plasma membrane, where its lipid substrate
is located [42,43]. Tyrosine phosphorylation of p85α
Y688 by Src family tyrosine kinases has also been shown
to increase PI3Kα activity [44], but the mechanism is
not known.
Phosphorylation of p85α S652 by PKC [45] (as well as
p85α S608 by p110α) has been reported to decrease
PI3Kα activity. S608 is in the inter-SH2 domain of p85α,
but is not within the section that has been observed to
contact p110α [37,38,46], therefore it is not clear
whether phosphorylation of S608 could influence the
inter-subunit interactions of p110α and p85α. A model
of the structure of p110 with the N- terminal SH2, C-
terminal SH2 and inter-SH2 domains of p85 [47] sug-
gests that the C-terminal part of the inter-SH2 domain
(containing S608) and the C-terminal SH2 domain has
the potential to contact the catalytic domain of p110.
Activation of PI3Kα due to binding of the p85α C-
terminal SH2 domain to phosphotyrosine-containing
proteins would be expected to be due to a conform-
ational change that disrupts the interface between the
p85α C-terminal SH2 domain and the p110α catalytic
domain, analogous to the disruption of the inhibitory
contact between the p85α N-terminal SH2 and the
p110α catalytic domain. In contrast, for phosphorylation
of S608 to decrease PI3Kα enzymatic activity, it would
have to stabilise this interface and oppose the phospho-
tyrosine binding-induced disruption. Regulation of
PI3Kα by stabilisation of inter-subunit interactions has
not yet been demonstrated.
Conclusions
Studies showing a decrease in PI kinase activity of wild-
type PI3Kα that correlated with increasing p85α S608
phosphorylation suggested the possibility that decreasedS608 phosphorylation of oncogenic PI3Kα could be a
mechanism underlying its increased PI kinase activity.
This study, in which highly purified, recombinant wild-
type and oncogenic, mutant PI3Kα was dephosphorylated
or fully phosphorylated on serine 608 in vitro (thus avoid-
ing point mutations which can potentially alter protein
structure and activity), found no evidence that phosphor-
ylation of S608 influenced PI kinase activity. In addition,
levels of phosphorylation of oncogenic PI3Kα were not
different to that of wild-type PI3Kα.
Methods
Production of recombinant proteins
cDNAs encoding full-length human p85α (PIK3R1_HU-
MAN, [Uniprot: P27986], aa1-724) or full-length human
wild-type or mutant (E545K or H1047R) p110α (PIK3-
CA_HUMAN, [Uniprot: P42336], aa1-1068) with an
additional C-terminal spacer (PGG) and a Glu- or EE-
epitope tag (EFMPME) [18,48] were subcloned into the
transfer plasmid pBlueBac4. Recombinant baculoviruses
were produced by co-transfection of these transfer plas-
mids into Sf9 insect cells with Bac-N-Blue baculovirus
DNA (Invitrogen), then plaque purified and amplified as
described [49]. EE-epitope tagged p110α (p110αEE) and
p85α were co-expressed in exponentially growing Sf9
cells (density = 1.5-2 × 106 cells/ml) by infection with re-
combinant baculoviruses at a multiplicity of infection
(MOI) of between 1 and 10. Wild-type or mutant
p110αEE/p85α complexes were purified to homogeneity
by anti-EE tag affinity chromatography and anion ex-
change chromatography as previously described [18,50].
The concentrations of purified, recombinant PI3Ks were
quantified by UV spectroscopy using a molar extinction
coefficient of 264115 M-1 cm-1.
Gel electrophoresis
Recombinant p110αEE/p85α complexes were separated by
SDS-PAGE using 10% Tris-glycine gels. Fast Coomassie
Blue staining and destaining was carried out using a
microwave oven as described [51].
Phosphoinositide 3-kinase assays
PI3K assays were carried out essentially as previously
described [18,52,53] in 20 mM Tris pH7.5, 150 mM
NaCl (TBS) containing 5 mM 2-mercaptoethanol. PI
kinase assays contained 2 mM MgCl2, 2 mM MnCl2,
0.2 mM ATP, 5–10 μCi [32P]γATP, 500 μg/ml of phos-
phatidylinositol (PI) and 250 μg/ml of phosphatidylserine
(PS). Extracted phospholipids were separated by thin
layer chromatography in 65% 1-propanol, 0.7 M acetic
acid, 50 mM phosphoric acid, exposed to a phosphor
screen (Molecular Dynamics) and analysed using Image-
Quant software (GE Healthcare). Michaelis-Menten
kinetics for phosphorylation of PI and PI-(4,5)-P2 were
Layton et al. BMC Biochemistry 2012, 13:30 Page 8 of 9
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concentration of ATP was varied between 0 and 125 μM.
Reactions were stopped after 20 min using 1 M HCl.
Protein kinase assays
Protein kinase assays were carried out in TBS containing
2 mM MgCl2, 2 mM MnCl2, 0.2 mM ATP and 5–10 μCi
[32P]γATP. Phosphorylated proteins were separated from
free [32P]γATP by SDS-PAGE as described above. Gels
were fixed and stained with Coomassie Blue, then dried,
exposed to a phosphor screen and analysed as described
above.
Phosphatase treatment
500 ng recombinant PI3K was mixed with 2–10 U re-
combinant Calf Intestinal Alkaline Phosphatase, 0.5-2 U
Antarctic Phosphatase or 8–40 U Lambda (λ) Protein
Phosphatase (NEB) and assayed for PI kinase activity or
protein kinase activity as described above.
In vitro phosphorylation of recombinant p110αEE/p85α
25 μg purified wild type or mutant p110αEE/p85α com-
plex was incubated with or without 1 mM ATP in the
presence of 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM
2-mercaptoethanol, 2 mM MgCl2 and 2 mM MnCl2 at
room temperature for 16 hr. Phosphorylated or mock
phosphorylated PI3Kα was buffer exchanged into TBS
containing 10 mM 2-mercaptoethanol using Sephadex
G-25 (GE Life Sciences) and concentrated using centri-
fugal filters (Amicon Ultra15 10,000 NMWL, Millipore).
250 ng of phosphorylated or mock phosphorylated (con-
trol) PI3Kα was assayed for PI kinase activity or protein
kinase activity as described above.
Phosphorylation sites on p110αEE/p85α were mapped
by digesting 2 μg aliquots of phosphorylated or mock
phosphorylated p110αEE/p85α with 0.1 μg trypsin
(Worthington) then purifying phosphopeptides using Fe3
+ immobilised metal affinity chromatography (IMAC) as
described [54]. Phosphopeptides were identified by
peptide mass fingerprinting using a QSTAR oMALDI-
QqTOF (Applied Biosystems/PE Sciex).
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